2018 Laureate
Current position
Research Scientist (CRCN), Team Leader.
Host Institution
Jean Bernard Center, INSERM U944, St Louis Hospital; Paris, France.
alexandre.puissant@inserm.fr
Alexandre Puissant and his research group are investigating the cellular mechanisms underlying acute myeloid leukemia (AML) development and chemoresistance using cutting-edge screening technologies intended to modulate gene function. These technologies are applied on several mouse models of AML which reproduces closely the human pathology.
• 2011: Doctor of Science, Ph.D., University of Nice-Sophia Antipolis, Nice, France, Patrick Auberger’s laboratory.
• 2011-2016: Post-doctoral fellow, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA, Kimberly Stegmaier’s lab.
• 2016: Research Scientist (INSERM CRCN, permanent position).
• 2017: Group leader at the INSERM Unit U944, St Louis Hospital, Paris, France.
• 2017: Starting Grant from the European Research Council (ERC).
• 2017: ATIP/AVENIR Research Grant, French Educational and Research Ministry. Principal Investigator.
• 2016: Laurette Fugain Award, Laurette Fugain Association.
• 2011: Award for young researcher, Bettencourt-Schueller Foundation.
SYK is a critical regulator of FLT3 in acute myeloid leukemia.
Feb 2014, Cancer Cell
Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Mar 2013, Cancer Discov.
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.
Aug 2012, J Mol Cell Biol